HHC-induced Rhabdomyolysis and Acute Kidney Injury: A Toxicological Case Report

Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid that has recently emerged on the global market as a \"legal\" alternative to THC. Despite its availability, clinical reports indicate that HHC-induced rhabdomyolysis can lead to severe complications. This case study details a significant toxicological event involving a 35-year-old male who suffered multiple organ issues after HHC use.

Clinical Presentation and Management

The patient, a chronic smoker of tobacco and HHC products, experienced a tonic-clonic seizure followed by a coma. Upon admission, his clinical course was complicated by severe rhabdomyolysis. This condition caused muscle breakdown products to enter his system, eventually resulting in acute kidney injury (AKI). He spent 11 days in the intensive care unit (ICU) and received supportive care. Fortunately, the patient recovered without requiring dialysis and was discharged after 15 days.

Insights from Toxicokinetics and Metabolomics

Understanding the Pathophysiology of HHC-induced rhabdomyolysis

Researchers conducted a comprehensive toxicological exploration of the patient's biological matrices. Using ultra-high performance liquid chromatography and high-resolution mass spectrometry, they identified 35 HHC metabolites. The study revealed that HHC concentration correlates with phenylalanine levels. Additionally, creatinine and creatine kinase levels showed a link to the carnitine pathway and dicarboxylic acids. These results suggest that HHC significantly alters biochemical pathways like β-oxidation and ω-oxidation.

Clinical Significance for Physicians

This case corroborates findings that semi-synthetic cannabinoids carry potent toxic risks. Doctors must stay vigilant as these substances often evade standard drug screening protocols. Early recognition of symptoms like seizures and muscle pain is vital. Aggressive fluid resuscitation remains the cornerstone of managing rhabdomyolysis-induced renal failure. Furthermore, monitoring metabolomic changes may provide new insights into cannabinoid toxicity in the future.

Frequently Asked Questions

What are the signs of HHC-induced rhabdomyolysis?

Common signs include severe muscle pain, weakness, and dark-colored urine. In severe cases, it can present alongside neurological symptoms like seizures or coma, as seen in this report.

How is acute kidney injury from cannabinoids treated?

Treatment is primarily supportive. It focuses on aggressive intravenous hydration to maintain urine output and prevent renal tubular damage from myoglobin. ICU monitoring may be necessary for severe cases.

Are semi-synthetic cannabinoids legal in India?

The legal status of semi-synthetic cannabinoids like HHC is complex. They often fall under the broad definitions of the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Clinicians should treat any synthetic derivative as a high-risk substance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Thiebot P et al. Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. J Cannabis Res. 2026 May 09. doi: 10.1186/s42238-026-00435-7. PMID: 42106886.


2. World Health Organization. Hexahydrocannabinol (HHC) Critical Review Report. Expert Committee on Drug Dependence, 47th Meeting. 2024.


3. Höfert L et al. Preliminary pharmacokinetic and psychophysical investigations after controlled oral and inhalative consumption of hexahydrocannabinol (HHC). Journal of Analytical Toxicology. 2024.